The global Glucagon like Peptide 1 Receptor Agonist market size is USD 23514.2 million in 2024.

According to Cognitive Market Research, the global Glucagon like Peptide 1 Receptor Agonist market size will be USD 23514.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 10.60% from 2024 to 2031.North America held the major market share for more than 40% of the global revenue with a market size of USD 9405.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.Europe accounted for a market share of over 30% of the global revenue with a market size of USD 7054.26 million.Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 5408.27 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.Latin America had a market share of more than 5% of the global revenue with a market size of USD 1175.71 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031.Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 470.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2031.The Hospital Pharmacies held the highest Glucagon like Peptide 1 Receptor Agonist market revenue share in 2024.  Market Dynamics of Glucagon like Peptide 1 Receptor Agonist MarketKey Drivers for Glucagon like Peptide 1 Receptor Agonist MarketRising Prevalence of Type 2 Diabetes and Obesity to Increase the Demand GloballyOne of the main causes is the growth in type 2 diabetes and obesity rates worldwide. The increasing number of patients is a result of sedentary lifestyles, poor food choices, and lifestyle modifications. Type 2 diabetes is becoming more common as the world's population ages, which is driving up the need for efficient therapies like GLP-1 RAs. For instance, according to IDF forecasts, 783 million adults, or 1 in 8 of the population, will have diabetes by 2045—a 46% rise. Type 2 diabetes, which is caused by a combination of genetic, environmental, demographic, and socioeconomic variables, affects more than 90% of the diabetes population. The primary causes of the growth in type 2 diabetes include urbanization, population ageing, a decline in physical activity, and an increase in the incidence of overweight and obesity.Growing Collaboration to Propel Market GrowthThe increasing collaboration in the market is expected to propel the market expansion during the forecast period. For instance, in November 2023, for the treatment of obesity, type-2 diabetes, and other cardiometabolic disorders, AstraZeneca and Eccogene have entered into an exclusive licensing agreement for ECC5004, an experimental oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA). The Phase I trial's first findings indicate that ECC5004 has a distinct clinical profile from placebo, with good tolerability and encouraging reductions in body weight and glucose at all tested dose levels.Restraint Factor for the Glucagon like Peptide 1 Receptor Agonist MarketAvailability of Alternatives and Stringent Regulations to Limit the SalesCompetitive options are provided by other families of diabetes drugs, including insulin, DPP-4 inhibitors, and SGLT-2 inhibitors. Physician preference or patient-specific circumstances may determine which of these options is favored. The use of more costly GLP-1 RAs may be constrained by the availability of less priced generic medications in other diabetes treatment classes. Furthermore, the market introduction of new GLP-1 RA medicines may be delayed because of the rigorous regulatory approval process. It takes time and money to meet safety and efficacy standards. For pharmaceutical businesses, post-marketing surveillance is necessary to evaluate long-term safety and is often costly and hard due to ongoing regulatory scrutiny.Impact of Covid-19 on the Glucagon like Peptide 1 Receptor Agonist MarketThere are several ways in which the COVID-19 pandemic has affected the market for Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA). The pandemic seriously disrupted the pharmaceutical industry's supply chain and production of GLP-1 RAs, among other goods. The distribution and manufacturing of these drugs were impacted by restrictions and lockdowns. GLP-1 RA production was impacted by shortages of raw materials and active pharmaceutical ingredients (APIs). Furthermore,...